Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 1
2006 1
2007 4
2008 4
2009 9
2010 17
2011 7
2012 10
2013 9
2014 6
2015 9
2016 3
2017 3
2018 3
2019 4
2020 3
2021 5
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Results by year

Filters applied: . Clear all
Page 1
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.
Kawashima Y, Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Seike M, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Kawashima Y, et al. Among authors: miyazaki m. Lancet Respir Med. 2022 Jan;10(1):72-82. doi: 10.1016/S2213-2600(21)00166-1. Epub 2021 Aug 26. Lancet Respir Med. 2022. PMID: 34454653 Clinical Trial.
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Saito H, et al. Among authors: miyazaki m. Lancet Oncol. 2019 May;20(5):625-635. doi: 10.1016/S1470-2045(19)30035-X. Epub 2019 Apr 8. Lancet Oncol. 2019. PMID: 30975627 Clinical Trial.
Regulation of lymphoid-myeloid lineage bias through regnase-1/3-mediated control of Nfkbiz.
Uehata T, Yamada S, Ori D, Vandenbon A, Giladi A, Jelinski A, Murakawa Y, Watanabe H, Takeuchi K, Toratani K, Mino T, Kiryu H, Standley DM, Tsujimura T, Ikawa T, Kondoh G, Landthaler M, Kawamoto H, Rodewald HR, Amit I, Yamamoto R, Miyazaki M, Takeuchi O. Uehata T, et al. Among authors: miyazaki m. Blood. 2024 Jan 18;143(3):243-257. doi: 10.1182/blood.2023020903. Blood. 2024. PMID: 37922454 Free PMC article.
Hematopoietic cell-derived IL-15 supports NK cell development in scattered and clustered localization within the bone marrow.
Abe S, Asahi T, Hara T, Cui G, Shimba A, Tani-Ichi S, Yamada K, Miyazaki K, Miyachi H, Kitano S, Nakamura N, Kikuta J, Vandenbon A, Miyazaki M, Yamada R, Ohteki T, Ishii M, Sexl V, Nagasawa T, Ikuta K. Abe S, et al. Among authors: miyazaki m. Cell Rep. 2023 Sep 26;42(9):113127. doi: 10.1016/j.celrep.2023.113127. Epub 2023 Sep 19. Cell Rep. 2023. PMID: 37729919 Free article.
The establishment of B versus T cell identity.
Miyazaki K, Miyazaki M, Murre C. Miyazaki K, et al. Among authors: miyazaki m. Trends Immunol. 2014 May;35(5):205-10. doi: 10.1016/j.it.2014.02.009. Epub 2014 Mar 26. Trends Immunol. 2014. PMID: 24679436 Free PMC article. Review.
94 results